Clinical recognition and management of patients with prediabetes

Jane W. Njeru, M. Regina Castro, Karina Gonzalez Carta, Gyorgy Simon, Pedro J. Caraballo

Research output: Contribution to journalArticle

Abstract

Objective: Early identification and management of prediabetes is critical to prevent progression to diabetes. We aimed to assess whether prediabetes is appropriately recognized and managed among patients with impaired fasting glucose (IFG). Methods: We carried out an observational study of Olmsted County residents evaluated at the Mayo Clinic between 1999-2017. We randomly selected 108 subjects with biochemical criteria of IFG and 105 normoglycemic subjects. We reviewed their health records at baseline (1999-2004) and during follow up (2005-2017) collecting demographic and clinical data including vitals, diagnoses, laboratory, and medications associated with cardiovascular comorbidities. The main outcome was documentation of any recognition of prediabetes and management recommendations (lifestyle changes and/or medications). Results: At baseline (1999-2004), 26.85% (29/108) of subjects with IFG were recognized as having prediabetes, and of these 75.86% (22/29) received management recommendations with 6.9% (2/29) getting metformin. During follow-up (2005-2017), 26.67% (28/105) of initial cohort of normoglycemic subjects developed incident IFG and of these, 85.71% (24/28) were recognized as having prediabetes, and 58.33% (14/24) received management recommendations. During the entire study period, 62.50% (85/136) were recognized as having prediabetes of which 75.29% (64/85) had documented management recommendations. High body mass index (BMI) (≥35) was associated with increased recognition (odds ratio [OR] 3.66; confidence interval [CI] 1.065, 12.500; P = .0395), and normal BMI (<25) was associated with a lack of recognition (OR 0.146; CI 0.189, 0.966; P = .0413). Conclusion: Despite evidence supporting the efficacy of lifestyle changes and medications in managing prediabetes, this condition is not fully recognized in routine clinical practice. Increased awareness of diagnostic criteria and appropriate management are essential to enhance diabetes prevention.

Original languageEnglish (US)
Pages (from-to)545-553
Number of pages9
JournalEndocrine Practice
Volume25
Issue number6
DOIs
StatePublished - Jun 1 2019

Fingerprint

Prediabetic State
Fasting
Glucose
Life Style
Body Mass Index
Odds Ratio
Confidence Intervals
Clinical Laboratory Techniques
Metformin
Documentation
Observational Studies
Comorbidity
Demography
Health

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Clinical recognition and management of patients with prediabetes. / Njeru, Jane W.; Castro, M. Regina; Carta, Karina Gonzalez; Simon, Gyorgy; Caraballo, Pedro J.

In: Endocrine Practice, Vol. 25, No. 6, 01.06.2019, p. 545-553.

Research output: Contribution to journalArticle

Njeru, Jane W. ; Castro, M. Regina ; Carta, Karina Gonzalez ; Simon, Gyorgy ; Caraballo, Pedro J. / Clinical recognition and management of patients with prediabetes. In: Endocrine Practice. 2019 ; Vol. 25, No. 6. pp. 545-553.
@article{e6e94b7f982b42fdabdc33b48cb0c755,
title = "Clinical recognition and management of patients with prediabetes",
abstract = "Objective: Early identification and management of prediabetes is critical to prevent progression to diabetes. We aimed to assess whether prediabetes is appropriately recognized and managed among patients with impaired fasting glucose (IFG). Methods: We carried out an observational study of Olmsted County residents evaluated at the Mayo Clinic between 1999-2017. We randomly selected 108 subjects with biochemical criteria of IFG and 105 normoglycemic subjects. We reviewed their health records at baseline (1999-2004) and during follow up (2005-2017) collecting demographic and clinical data including vitals, diagnoses, laboratory, and medications associated with cardiovascular comorbidities. The main outcome was documentation of any recognition of prediabetes and management recommendations (lifestyle changes and/or medications). Results: At baseline (1999-2004), 26.85{\%} (29/108) of subjects with IFG were recognized as having prediabetes, and of these 75.86{\%} (22/29) received management recommendations with 6.9{\%} (2/29) getting metformin. During follow-up (2005-2017), 26.67{\%} (28/105) of initial cohort of normoglycemic subjects developed incident IFG and of these, 85.71{\%} (24/28) were recognized as having prediabetes, and 58.33{\%} (14/24) received management recommendations. During the entire study period, 62.50{\%} (85/136) were recognized as having prediabetes of which 75.29{\%} (64/85) had documented management recommendations. High body mass index (BMI) (≥35) was associated with increased recognition (odds ratio [OR] 3.66; confidence interval [CI] 1.065, 12.500; P = .0395), and normal BMI (<25) was associated with a lack of recognition (OR 0.146; CI 0.189, 0.966; P = .0413). Conclusion: Despite evidence supporting the efficacy of lifestyle changes and medications in managing prediabetes, this condition is not fully recognized in routine clinical practice. Increased awareness of diagnostic criteria and appropriate management are essential to enhance diabetes prevention.",
author = "Njeru, {Jane W.} and Castro, {M. Regina} and Carta, {Karina Gonzalez} and Gyorgy Simon and Caraballo, {Pedro J.}",
year = "2019",
month = "6",
day = "1",
doi = "10.4158/EP-2018-0485",
language = "English (US)",
volume = "25",
pages = "545--553",
journal = "Endocrine Practice",
issn = "1530-891X",
publisher = "American Association of Clinical Endocrinology",
number = "6",

}

TY - JOUR

T1 - Clinical recognition and management of patients with prediabetes

AU - Njeru, Jane W.

AU - Castro, M. Regina

AU - Carta, Karina Gonzalez

AU - Simon, Gyorgy

AU - Caraballo, Pedro J.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - Objective: Early identification and management of prediabetes is critical to prevent progression to diabetes. We aimed to assess whether prediabetes is appropriately recognized and managed among patients with impaired fasting glucose (IFG). Methods: We carried out an observational study of Olmsted County residents evaluated at the Mayo Clinic between 1999-2017. We randomly selected 108 subjects with biochemical criteria of IFG and 105 normoglycemic subjects. We reviewed their health records at baseline (1999-2004) and during follow up (2005-2017) collecting demographic and clinical data including vitals, diagnoses, laboratory, and medications associated with cardiovascular comorbidities. The main outcome was documentation of any recognition of prediabetes and management recommendations (lifestyle changes and/or medications). Results: At baseline (1999-2004), 26.85% (29/108) of subjects with IFG were recognized as having prediabetes, and of these 75.86% (22/29) received management recommendations with 6.9% (2/29) getting metformin. During follow-up (2005-2017), 26.67% (28/105) of initial cohort of normoglycemic subjects developed incident IFG and of these, 85.71% (24/28) were recognized as having prediabetes, and 58.33% (14/24) received management recommendations. During the entire study period, 62.50% (85/136) were recognized as having prediabetes of which 75.29% (64/85) had documented management recommendations. High body mass index (BMI) (≥35) was associated with increased recognition (odds ratio [OR] 3.66; confidence interval [CI] 1.065, 12.500; P = .0395), and normal BMI (<25) was associated with a lack of recognition (OR 0.146; CI 0.189, 0.966; P = .0413). Conclusion: Despite evidence supporting the efficacy of lifestyle changes and medications in managing prediabetes, this condition is not fully recognized in routine clinical practice. Increased awareness of diagnostic criteria and appropriate management are essential to enhance diabetes prevention.

AB - Objective: Early identification and management of prediabetes is critical to prevent progression to diabetes. We aimed to assess whether prediabetes is appropriately recognized and managed among patients with impaired fasting glucose (IFG). Methods: We carried out an observational study of Olmsted County residents evaluated at the Mayo Clinic between 1999-2017. We randomly selected 108 subjects with biochemical criteria of IFG and 105 normoglycemic subjects. We reviewed their health records at baseline (1999-2004) and during follow up (2005-2017) collecting demographic and clinical data including vitals, diagnoses, laboratory, and medications associated with cardiovascular comorbidities. The main outcome was documentation of any recognition of prediabetes and management recommendations (lifestyle changes and/or medications). Results: At baseline (1999-2004), 26.85% (29/108) of subjects with IFG were recognized as having prediabetes, and of these 75.86% (22/29) received management recommendations with 6.9% (2/29) getting metformin. During follow-up (2005-2017), 26.67% (28/105) of initial cohort of normoglycemic subjects developed incident IFG and of these, 85.71% (24/28) were recognized as having prediabetes, and 58.33% (14/24) received management recommendations. During the entire study period, 62.50% (85/136) were recognized as having prediabetes of which 75.29% (64/85) had documented management recommendations. High body mass index (BMI) (≥35) was associated with increased recognition (odds ratio [OR] 3.66; confidence interval [CI] 1.065, 12.500; P = .0395), and normal BMI (<25) was associated with a lack of recognition (OR 0.146; CI 0.189, 0.966; P = .0413). Conclusion: Despite evidence supporting the efficacy of lifestyle changes and medications in managing prediabetes, this condition is not fully recognized in routine clinical practice. Increased awareness of diagnostic criteria and appropriate management are essential to enhance diabetes prevention.

UR - http://www.scopus.com/inward/record.url?scp=85068049774&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068049774&partnerID=8YFLogxK

U2 - 10.4158/EP-2018-0485

DO - 10.4158/EP-2018-0485

M3 - Article

C2 - 30865535

AN - SCOPUS:85068049774

VL - 25

SP - 545

EP - 553

JO - Endocrine Practice

JF - Endocrine Practice

SN - 1530-891X

IS - 6

ER -